Cutaneous Oncology News

HemOnc Today is pleased to announce plans for a 3-day CME meeting designed to offer expert perspectives on advances in cancer treatment.

The FDA approved pembrolizumab for adjuvant treatment of patients who have melanoma with lymph node involvement who underwent complete resection.

Steven O’Day, MD, has been named executive director of John Wayne Cancer Institute and Cancer Clinic at Providence St. John’s Health Center.

The American Academy of Dermatology released new guidelines on melanoma treatment.

Igor Puzanov, MD, MSCI, FACP, received the Melanoma Foundation Award for outstanding and lifelong contributions to melanoma research.

The FDA granted accelerated approval to larotrectinib for the treatment of adults and children with solid tumors that have a neurotrophic receptor tyrosine kinase gene fusion without a known acquired resistance mutation.

NEW YORK — The addition of spartalizumab to dabrafenib and trametinib appeared safe and effective for previously untreated patients with advanced BRAF V600-mutant unresectable or metastatic melanoma, according to study results presented at Chemotherapy Foundation Symposium.

Patients with chronic lymphocytic leukemia or small lymphocytic lymphoma could benefit from active melanoma surveillance, according to study results published in Leukemia Research.

Adjuvant treatment with dabrafenib plus trametinib demonstrated a durable RFS benefit compared with placebo for patients with resected stage III BRAF V600-mutant melanoma, according to long-term follow-up from a randomized phase 3 trial.

Researchers observed a significant reduction in overall risk of cancer among individuals who consumed organic food at a high frequency, according to a new study published in JAMA Internal Medicine.